Drugs / Inetetamab
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05016544 | Jul 2021 → Aug 2023 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 210 trials · 1 missed | ||||||
| Phase 2 | NCT07182721 | Sep 2025 → Sep 2028 expected | HER2 positive breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05621434 | Dec 2022 → Dec 2024 | HER2 positive breast carcinoma | Fujian Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05444998 | Nov 2022 → Aug 2023 | breast cancer | Xijing Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05328440 | May 2022 → Jun 2024 | breast cancer | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05823623 | Feb 2022 → Dec 2023 | breast cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT05749016 | Nov 2021 → Jul 2023 | chemotherapy-induced toxicity, female breast carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | Missed primary |
| Phase 2 | NCT04963595 | Aug 2021 → Jan 2023 | breast cancer | Zhiyong Yu | Unknown | No outcome recorded |
| Phase 2 | NCT04941885 | Jun 2021 → Jul 2023 | breast cancer | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04681287 | Apr → Nov 2021 | HER2 positive breast carcinoma | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04681911 | Sep 2020 → Sep 2023 | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07366840 | Jan 2026 → Jan 2028 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04736589 | Feb 2021 → Feb 2024 overdue | breast cancer | Peking Union Medical College | Not yet recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06818773 | Feb 2025 → Dec 2026 expected | HER2 positive breast carcinoma, biliary tract cancer | Eastern Hepatobiliary Surgery Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06578299 | Aug 2024 → Mar 2026 overdue | breast cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05291910 | Mar 2022 → Dec 2024 | breast cancer | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06234137 | Nov 2021 → Jul 2025 overdue | breast cancer | Wang Ouchen | Recruiting | No outcome recorded |
| — | NCT06015100 | Feb 2021 → Aug 2023 | breast cancer | Yan Xue | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT06641544 Background | Oct 2024 → Dec 2027 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inetetamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05328440 ↗ |
| Known as | Cipterbin | “Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor...” NCT04681287 ↗1“Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect.” NCT05749016 ↗ |
| Known as | Inetetamab for injection | “Inetetamab for injection” NCT05621434 ↗ |
| Action | Inhibit | “inetetamab (an anti-HER2 monoclonal antibody)” PMID 41593669 ↗ Jan 2026 |
| Modality | Monoclonal antibody | “inetetamab (an anti-HER2 monoclonal antibody)” PMID 41593669 ↗ Jan 2026 |
| Route | Intravenous | “IV infusion” NCT04736589 ↗ |
| Target | ERBB2 | “Inetetamab could bind to HER2 extracellular domain (ECD) with high affinity” NCT04963595 ↗ |